SCHEMBL614357

SCHEMBL614357

NC(=O)COc1ccc(Nc2nc3ccc(-c4cc(O)ccc4Cl)cn3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.43
WEE1 P30291 1/20 0.43
TTK P33981 3/20 0.42
POLB P06746 1/20 0.42
BRAF P15056 2/20 0.41
LRRK2 Q5S007 2/20 0.41
SRC P12931 4/20 0.41
YES1 P07947 2/20 0.41
PDGFRB P09619 2/20 0.41
ABL1 P00519 2/20 0.41
CIT O14578 1/20 0.41
GAK O14976 1/20 0.41
EPHB6 O15197 1/20 0.41
RIPK2 O43353 1/20 0.41
PRKD3 O94806 1/20 0.41
LCK P06239 1/20 0.41
RET P07949 1/20 0.41
BCR P11274 1/20 0.41
EPHA2 P29317 1/20 0.41
EPHB2 P29323 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL613791 0.91 SRC (0.42) SYKWEE1TTKBRAFLRRK2
SCHEMBL612376 0.87 SRC (0.46) TTKBRAFLRRK2SRCYES1
SCHEMBL615192 0.85 LRRK2 (0.48) SYKTTKBRAFLRRK2SRC
SCHEMBL613798 0.83 ESR1 (0.45) WEE1TTKBRAFLRRK2SRC
SCHEMBL613040 0.82 LRRK2 (0.52) TTKBRAFLRRK2SRCYES1
SCHEMBL614726 0.82 JAK3 (0.43) TTKPOLBBRAFLRRK2SRC
SCHEMBL614725 0.82 JAK3 (0.43) TTKPOLBBRAFLRRK2SRC
SCHEMBL612970 0.82 SRC (0.62) BRAFSRCYES1PDGFRBABL1
SCHEMBL613005 0.81 LRRK2 (0.44) TTKBRAFLRRK2SRCYES1
SCHEMBL613379 0.81 LRRK2 (0.47) TTKBRAFLRRK2SRCYES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US claimed
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041195-A1 Heterocyclic compounds MAP3K1, MAP3K5, MAP3K2 SYK 1046/4885WEE1 727/4885TTK 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.